Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment

Overview

Journal Front Chem

Specialty Chemistry

Date 2020 Nov 16

PMID 33195053

Citations 30

Authors

Jingshun Zhang

Ying Xu

Dandan Li

Lulu Fu

Xueying Zhang

Yigang Bao

Lianwen Zheng

Affiliations

Soon will be listed here.

Abstract

LAT1 is a member of the system L transporter family. The main role of the LAT1 is to transport specific amino acids through cell membranes to provide nutrients to cells and participate in several metabolic pathways. It also contributes to the transport of hormones and some drugs, which are essential for the development and treatment of some diseases. In recent years, many studies have shown that LAT1 is related to cancer, obesity, diabetes, and other diseases. However, the specific mechanism underlying the influence of LAT1 on such conditions remains unclear. Through the increasing number of studies on LAT1, we have obtained a preliminary understanding on the function of LAT1 in diseases. These studies also provide a theoretical basis for finding treatments for LAT1-related diseases, such as cancer. This review summarizes the function and mechanism of LAT1 in different diseases and the treatment of LAT1-related diseases. It also provides support for the development of novel and reliable disease treatments.

Citing Articles

Targeting Surface Markers in Anaplastic Thyroid Cancer: Future Directions in Ligand-bound Therapy.

Pakkianathan J, Chan S, Cruz J, Ewan K, Simental A, Khan S J Endocr Soc. 2025; 9(4):bvaf035.

PMID: 40071065 PMC: 11893542. DOI: 10.1210/jendso/bvaf035.

The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications.

Kim S, Jung U, Kim S J Clin Med. 2025; 14(2).

PMID: 39860392 PMC: 11765772. DOI: 10.3390/jcm14020386.

Identification of potential biomarkers from amino acid transporter in the activation of hepatic stellate cells via bioinformatics.

Zhao Y, Xu X, Cai H, Wu W, Wang Y, Huang C Front Genet. 2024; 15:1499915.

PMID: 39698464 PMC: 11652522. DOI: 10.3389/fgene.2024.1499915.

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K Int J Mol Sci. 2024; 25(22).

PMID: 39596451 PMC: 11594329. DOI: 10.3390/ijms252212386.

Pterostilbene Targets Hallmarks of Aging in the Gene Expression Landscape in Blood of Healthy Rats.

Tello-Palencia M, Yang T, Sularz O, Demers L, Ma Y, Boycott C Mol Nutr Food Res. 2024; 68(24):e2400662.

PMID: 39562169 PMC: 11670294. DOI: 10.1002/mnfr.202400662.

References

Duelli R, Enerson B, Gerhart D, Drewes L . Expression of large amino acid transporter LAT1 in rat brain endothelium. J Cereb Blood Flow Metab. 2000; 20(11):1557-62. DOI: 10.1097/00004647-200011000-00005. View

Lynch C, Adams S . Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014; 10(12):723-36. PMC: 4424797. DOI: 10.1038/nrendo.2014.171. View

Friesema E, Docter R, Moerings E, Verrey F, Krenning E, Hennemann G . Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endocrinology. 2001; 142(10):4339-48. DOI: 10.1210/endo.142.10.8418. View

Adeva M, Calvino J, Souto G, Donapetry C . Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino Acids. 2011; 43(1):171-81. DOI: 10.1007/s00726-011-1088-7. View

Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y . Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008; 62(2):493-503. DOI: 10.1227/01.neu.0000316018.51292.19. View

Elorza A, Soro-Arnaiz I, Melendez-Rodriguez F, Rodriguez-Vaello V, Marsboom G, de Carcer G . HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell. 2012; 48(5):681-91. DOI: 10.1016/j.molcel.2012.09.017. View

Marshall A, van Geldermalsen M, Otte N, Anderson L, Lum T, Vellozzi M . LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma. Int J Cancer. 2016; 139(11):2529-39. DOI: 10.1002/ijc.30371. View

Smith A, King J, West P, Ludwig M, Donley E, Burrier R . Amino Acid Dysregulation Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism Spectrum Disorder. Biol Psychiatry. 2018; 85(4):345-354. PMC: 6837735. DOI: 10.1016/j.biopsych.2018.08.016. View

Salisbury T, Arthur S . The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer. Int J Mol Sci. 2018; 19(8). PMC: 6121554. DOI: 10.3390/ijms19082373. View

10.

Yamamoto Y, Sawa R, Wake I, Morimoto A, Okimura Y . Glucose-mediated inactivation of AMP-activated protein kinase reduces the levels of L-type amino acid transporter 1 mRNA in C2C12 cells. Nutr Res. 2017; 47:13-20. DOI: 10.1016/j.nutres.2017.08.003. View

11.

Hayashi K, Jutabha P, Endou H, Anzai N . c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells. Oncol Rep. 2012; 28(3):862-6. DOI: 10.3892/or.2012.1878. View

12.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N . Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 2009; 66(1):120-6. DOI: 10.1016/j.lungcan.2008.12.015. View

13.

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung S . SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006; 127(1):125-37. DOI: 10.1016/j.cell.2006.08.033. View

14.

Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K . Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012; 107(4):632-8. PMC: 3419959. DOI: 10.1038/bjc.2012.310. View

15.

Wang R, Green D . Metabolic checkpoints in activated T cells. Nat Immunol. 2012; 13(10):907-15. DOI: 10.1038/ni.2386. View

16.

Sato K, Miyamoto M, Takano M, Furuya K, Tsuda H . Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. Virchows Arch. 2019; 474(6):701-710. DOI: 10.1007/s00428-019-02520-0. View

17.

Araki K, Turner A, Shaffer V, Gangappa S, Keller S, Bachmann M . mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. PMC: 2710807. DOI: 10.1038/nature08155. View

18.

Moller L, Paulsen M, Koch R, Moats R, Guldberg P, Guttler F . Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab. 2005; 86 Suppl 1:S119-23. DOI: 10.1016/j.ymgme.2005.07.031. View

19.

Poncet N, Mitchell F, Ibrahim A, McGuire V, English G, Arthur J . The catalytic subunit of the system L1 amino acid transporter (slc7a5) facilitates nutrient signalling in mouse skeletal muscle. PLoS One. 2014; 9(2):e89547. PMC: 3935884. DOI: 10.1371/journal.pone.0089547. View

20.

Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H . Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathol Oncol Res. 2013; 19(4):649-56. DOI: 10.1007/s12253-013-9624-2. View